Julia Sun1, Alastair I Ilich2, Christina A Kim1, Michael P Chu1, Grace G Wong2, Sunita Ghosh3, Melanie Danilak2, Karen E Mulder1, Jennifer L Spratlin1, Carole R Chambers4, Michael B Sawyer5. 1. Department of Medical Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada. 2. Pharmacy Department, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada. 3. Clinical Trials Unit, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada. 4. Pharmacy Department, Tom Baker Cancer Centre, Calgary, Alberta, Canada. 5. Department of Medical Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada. Electronic address: michael.sawyer@albertahealthservices.ca.
Abstract
BACKGROUND: Capecitabine is used to treat colorectal (CRC) cancer. TRIO-013, a study examining capecitabine/oxaliplatin ± lapatinib in metastatic gastro-esophageal cancer did not show increases in overall survival (OS) with lapatinib. An analysis showed concurrent proton pump inhibitor (PPI) usage negatively impacted recurrence-free survival (RFS). We retrospectively studied PPI effects on capecitabine efficacy in early stage CRC and how capecitabine adjustments impacted RFS. METHODS: Early stage CRC patients taking monotherapy capecitabine treated from 2008 to 2012 were reviewed for demographics, medications, toxicities, and patient outcomes. RESULTS: Of 298 identified patients, 25.8% (n = 77) received concurrent PPIs. Five-year RFS was 74% versus 83% (hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.07-3.35; P = .03) in PPI versus non-PPI patients respectively. OS was 81% versus 78%, respectively (HR, 1.13; 95% CI, 0.60-2.14; P = .7). After accounting for gender, stage, age, and performance status, PPI patients tended toward decreased RFS (HR, 1.65; 95% CI, 0.93-2.94; P = .09). Capecitabine dose modifications affected outcomes. Five-year RFS was 84% in the control group, 100% in the treatment-delay group (P = .99), 67% in the dose reduction group (HR, 2.46; 95% CI, 1.23-4.93; P = .01), and 64% in the discontinuation group (HR, 2.27; 95% CI, 0.93-5.53; P = .07). Five-year OS was significantly less in the discontinuation group than control group (59% vs. 82%; HR, 3.27; 95% CI, 1.44-7.45; P = .005). CONCLUSIONS: PPIs appear to impact RFS; this may be due to PPIs preventing capecitabine tablet dissolution and absorption. Patients with dose reductions or who stopped treatment had worse outcomes than patients who continued with treatment at starting doses.
BACKGROUND:Capecitabine is used to treat colorectal (CRC) cancer. TRIO-013, a study examining capecitabine/oxaliplatin ± lapatinib in metastatic gastro-esophageal cancer did not show increases in overall survival (OS) with lapatinib. An analysis showed concurrent proton pump inhibitor (PPI) usage negatively impacted recurrence-free survival (RFS). We retrospectively studied PPI effects on capecitabine efficacy in early stage CRC and how capecitabine adjustments impacted RFS. METHODS: Early stage CRC patients taking monotherapy capecitabine treated from 2008 to 2012 were reviewed for demographics, medications, toxicities, and patient outcomes. RESULTS: Of 298 identified patients, 25.8% (n = 77) received concurrent PPIs. Five-year RFS was 74% versus 83% (hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.07-3.35; P = .03) in PPI versus non-PPI patients respectively. OS was 81% versus 78%, respectively (HR, 1.13; 95% CI, 0.60-2.14; P = .7). After accounting for gender, stage, age, and performance status, PPI patients tended toward decreased RFS (HR, 1.65; 95% CI, 0.93-2.94; P = .09). Capecitabine dose modifications affected outcomes. Five-year RFS was 84% in the control group, 100% in the treatment-delay group (P = .99), 67% in the dose reduction group (HR, 2.46; 95% CI, 1.23-4.93; P = .01), and 64% in the discontinuation group (HR, 2.27; 95% CI, 0.93-5.53; P = .07). Five-year OS was significantly less in the discontinuation group than control group (59% vs. 82%; HR, 3.27; 95% CI, 1.44-7.45; P = .005). CONCLUSIONS: PPIs appear to impact RFS; this may be due to PPIs preventing capecitabine tablet dissolution and absorption. Patients with dose reductions or who stopped treatment had worse outcomes than patients who continued with treatment at starting doses.
Authors: Sun Young Kim; Ji Sung Lee; Junho Kang; Satoshi Morita; Young Suk Park; Junichi Sakamoto; Kei Muro; Rui-Hua Xu; Tae Won Kim Journal: Oncologist Date: 2021-03-23
Authors: Michael P Chu; J Randolph Hecht; Dennis Slamon; Zev A Wainberg; Yung-Jue Bang; Paulo M Hoff; Alberto Sobrero; Shukui Qin; Karen Afenjar; Vincent Houe; Karen King; Sheryl Koski; Karen Mulder; Julie Price Hiller; Andrew Scarfe; Jennifer Spratlin; Yingjie J Huang; Saba Khan-Wasti; Neil Chua; Michael B Sawyer Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Devon J Boyne; Colleen A Cuthbert; Dylan E O'Sullivan; Tolulope T Sajobi; Robert J Hilsden; Christine M Friedenreich; Winson Y Cheung; Darren R Brenner Journal: JAMA Netw Open Date: 2019-05-03
Authors: Angel A T Uchiyama; Pedro A I A Silva; Moisés S M Lopes; Cheng T Yen; Eliza D Ricardo; Taciana Mutão; Jefferson R Pimenta; Larissa M Machado; Denis S Shimba; Renata D Peixoto Journal: Curr Oncol Date: 2021-02-03 Impact factor: 3.677
Authors: Devon J Boyne; Dylan E O'Sullivan; Emily V Heer; Robert J Hilsden; Tolulope T Sajobi; Winson Y Cheung; Darren R Brenner; Christine M Friedenreich Journal: Cancer Med Date: 2020-01-21 Impact factor: 4.452